SUNDANCE STRATEGIES, INC. financials

SUND CIK 0001171838

Source: EDGAR filings · Built 2026-06-19T03:11:24Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Working Capital -2.67M -1.29M -2.89M -2.24M -2.30M -850.73K
Net Debt 2.30M 2.96M 2.28M 2.16M
Return on Equity (ROE) 25.44% 30.89% 46.60% 55.01% 32.43% 29.87%
Return on Assets (ROA) -899.75% -541.40%
Current Ratio 0.06× 0.21× 0.00× 0.11× 0.01× 0.04×
Debt-to-Equity -0.39× -0.55× -0.38× -0.48×
Effective Tax Rate -0.15%
Cash Conversion Ratio 0.57× 0.36× 0.16× 0.29× 0.54× 0.67×
Accruals Ratio -3.86× -3.45×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Operating Expenses 50.00K 44.00K 57.00K 75.00K 75.00K 70.00K
Operating Income (Loss) -604.17K -531.41K -682.28K -690.71K -907.98K -828.45K
Income Tax Expense (Benefit) 4.15K
Net Income (Loss) Attributable to Parent -1.60M -1.83M -2.81M -2.77M -1.53M -1.11M
Earnings Per Share, Basic $-0.04 $-0.04 $-0.07 $-0.07 $-0.04
Weighted Average Number of Shares Outstanding, Basic 42.86M 41.69M 41.41M 41.22M 38.90M
Earnings Per Share, Diluted $-0.04 $-0.04 $-0.07
Weighted Average Number of Shares Outstanding, Diluted 42.86M 41.69M 41.41M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 168.65K 329.86K 553 267.97K 21.18K 28.78K
Assets, Current 178.20K 338.94K 8.85K 276.13K 30.57K 30.99K
Assets 178.20K 338.94K
Liabilities, Current 2.85M 1.63M 2.90M 2.51M 2.34M 881.72K
Liabilities 6.48M 6.28M 6.04M 5.30M 4.75M 3.76M
Stockholders' Equity Attributable to Parent -6.30M -5.94M -6.03M -5.03M -4.72M -3.73M
Common Stock, Shares, Outstanding 43.06M 42.26M 41.41M 41.41M 40.11M 37.83M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities -916.21K -666.64K -459.71K -813.21K -818.36K -750.29K
Net Cash Provided by (Used in) Financing Activities 755.00K 995.95K 192.30K 1.06M 810.76K 778.50K

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (SUND CIK 0001171838), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

NMTC

NeuroOne Medical Technologies Corporation

WEX

WEX Inc.

ELOX

ELOXX PHARMACEUTICALS, INC.